MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Metagenomi Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$0.81+0.03 (+3.55%)

Close on Oct 19, 2026

Market cap: $30.57M
P/E (TTM): –
Dividend yield: –

Metagenomi Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	25	52	45
Research & Development	94	109	94
General & Administrative	27	32	29
Operating Expenses	121	141	123
Operating Income	-96	-89	-78
Interest & Investment Income	9.47	15	15
Other Non-Operating Income	8.09	5.33	18
Asset Impairment Charges	–	1.04	0.02
Gain (Loss) on Sale of Assets	-0.50	-1.04	–
Pretax Income	-88	-84	-60
Income Tax Expense	-0.06	-5.51	8.03
Net Income incl. Noncontrolling Interests	-88	-78	-68
Net Income	-88	-78	-68
Net Income to Common	-88	-78	-68
EPS (Basic)(per share)	-2.36	-2.36	-20.05
EPS (Diluted)(per share)	-2.36	-2.36	-20.05
Shares Outstanding (Basic, Weighted)(shares)	37	33	3.40
Shares Outstanding (Diluted, Weighted)(shares)	37	33	3.40

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -398.9%
Net margin: -370.7%
Return on equity, FY2025: -44.7%

Financial strength

Current ratio: 4.50
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.2%

Valuation

P/E ratio: –
Price to sales: 1.21
Price to book: 0.27
Dividend yield: –